Traphaco Advancing Harmonization of Eastern and Western Medicine

Traphaco Joint Stock Company's parallel development strategy, seamlessly integrating premium Eastern medicine with high-quality Western medicine, represents a breakthrough in its business model, reinforcing its commitment to sustainable innovation and adherence to internationally recognized standards of quality and social responsibility.

In the past 50 years, Traphaco has made a solid standing in the Vietnamese pharmaceutical market thanks to its successful production and distribution of medicinal products from the country's rich natural resources. With its parallel product development strategy, Traphaco has further affirmed its position in the domestic market while preparing to enter the international market with high-quality products with unique cultural values from Vietnamese medicinal herbs.

Since its inception, Traphaco has pursued a sustainable development philosophy by preserving and promoting the value of domestic medicinal resources. This is part of its strategy of accompanying the community and the environment, helping create jobs and increase income for local people, especially in remote areas. This strategy was initiated by the GreenPlan Project - a project that aims to develop GACP-WHO-certified clean medicinal areas in order to protect natural resources and ensure a stable and sustainable supply for its Oriental medicine products.

Realizing the increasing market demand for Western medicine products, Traphaco has boldly invested in product research and development. With strict quality standards, the company has built a smart Western medicine plant using manufacturing robots to ensure consistent quality. In addition, Traphaco also cooperates with Daewoong, one of leading pharmaceutical corporations in South Korea, to take on technology to improve the quality of Occidental medicine products and reduce treatment costs for patients.

Traphaco's Western medicine products, such as new generation anticoagulants and lipid disorder treatment drugs, have been recognized by the Ministry of Health to meet bioequivalence standards with generic drugs. Very quickly since the start of 2022, Traphaco has 10 products announced by the Ministry of Health as bioequivalents. This is a proud achievement and a favorable first step to make the Traphaco brand stronger on the map of pharmaceutical manufacturers in Vietnam. With the high-quality Western medicine development strategy, Traphaco hopes to help reduce medical costs and expand access to quality medical services for people.

Traphaco's success with its premium Eastern medicine and high-quality Western medicine products also comes from its strong investment in environmentally friendly modern production technology. Traphaco owns a GMP-certified factory powered by advanced technologies. In the coming time, the company will launch an EU-GMP production line project. Traphaco is also the first pharmaceutical manufacturer in Vietnam to have an R&D laboratory that meets GLP-WHO standards (Good Laboratory Practice according to World Health Organization standards).

By Duy Anh, Vietnam Business Forum